Literature DB >> 22816378

Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels.

Erik Kohlbrenner1, Els Henckaerts, Kleopatra Rapti, Ronald E Gordon, R Michael Linden, Roger J Hajjar, Thomas Weber.   

Abstract

Adeno-associated virus (AAV)-based vectors have gained increasing attention as gene delivery vehicles in basic and preclinical studies as well as in human gene therapy trials. Especially for the latter two-for both safety and therapeutic efficacy reasons-a detailed characterization of all relevant parameters of the vector preparation is essential. Two important parameters that are routinely used to analyze recombinant AAV vectors are (1) the titer of viral particles containing a (recombinant) viral genome and (2) the purity of the vector preparation, most commonly assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by silver staining. An important, third parameter, the titer of total viral particles, that is, the combined titer of both genome-containing and empty viral capsids, is rarely determined. Here, we describe a simple and inexpensive method that allows the simultaneous assessment of both vector purity and the determination of the total viral particle titer. This method, which was validated by comparison with established methods to determine viral particle titers, is based on the fact that Coomassie Brilliant Blue, when bound to proteins, fluoresces in the infrared spectrum. Viral samples are separated by SDS-PAGE followed by Coomassie Brilliant Blue staining and gel analysis with an infrared laser-scanning device. In combination with a protein standard, our method allows the rapid and accurate determination of viral particle titers simultaneously with the assessment of vector purity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22816378      PMCID: PMC4015068          DOI: 10.1089/hgtb.2012.049

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  22 in total

1.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.

Authors:  S Zolotukhin; B J Byrne; E Mason; I Zolotukhin; M Potter; K Chesnut; C Summerford; R J Samulski; N Muzyczka
Journal:  Gene Ther       Date:  1999-06       Impact factor: 5.250

2.  Quantitation of protein on gels and blots by infrared fluorescence of Coomassie blue and Fast Green.

Authors:  Shen Luo; Nancy B Wehr; Rodney L Levine
Journal:  Anal Biochem       Date:  2005-11-17       Impact factor: 3.365

3.  Development of AAV serotype-specific ELISAs using novel monoclonal antibodies.

Authors:  Dirk Kuck; Andrea Kern; Jürgen A Kleinschmidt
Journal:  J Virol Methods       Date:  2006-11-28       Impact factor: 2.014

4.  Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2.

Authors:  D Grimm; A Kern; M Pawlita; F Ferrari; R Samulski; J Kleinschmidt
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

5.  Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material.

Authors:  Martin Lock; Susan McGorray; Alberto Auricchio; Eduard Ayuso; E Jeffrey Beecham; Véronique Blouin-Tavel; Fatima Bosch; Mahuya Bose; Barry J Byrne; Tina Caton; John A Chiorini; Abdelwahed Chtarto; K Reed Clark; Thomas Conlon; Christophe Darmon; Monica Doria; Anne Douar; Terence R Flotte; Joyce D Francis; Achille Francois; Mauro Giacca; Michael T Korn; Irina Korytov; Xavier Leon; Barbara Leuchs; Gabriele Lux; Catherine Melas; Hiroaki Mizukami; Philippe Moullier; Marcus Müller; Keiya Ozawa; Tina Philipsberg; Karine Poulard; Christina Raupp; Christel Rivière; Sigrid D Roosendaal; R Jude Samulski; Steven M Soltys; Richard Surosky; Liliane Tenenbaum; Darby L Thomas; Bart van Montfort; Gabor Veres; J Fraser Wright; Yili Xu; Olga Zelenaia; Lorena Zentilin; Richard O Snyder
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

6.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Authors:  Mariell Jessup; Barry Greenberg; Donna Mancini; Thomas Cappola; Daniel F Pauly; Brian Jaski; Alex Yaroshinsky; Krisztina M Zsebo; Howard Dittrich; Roger J Hajjar
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

7.  High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency.

Authors:  E Ayuso; F Mingozzi; J Montane; X Leon; X M Anguela; V Haurigot; S A Edmonson; L Africa; S Zhou; K A High; F Bosch; J F Wright
Journal:  Gene Ther       Date:  2009-12-03       Impact factor: 5.250

Review 8.  Manufacturing and characterizing AAV-based vectors for use in clinical studies.

Authors:  J F Wright
Journal:  Gene Ther       Date:  2008-04-17       Impact factor: 5.250

9.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Authors:  Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett
Journal:  Lancet       Date:  2009-10-23       Impact factor: 79.321

10.  Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors.

Authors:  N Zeltner; E Kohlbrenner; N Clément; T Weber; R M Linden
Journal:  Gene Ther       Date:  2010-03-25       Impact factor: 5.250

View more
  15 in total

1.  Quantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes.

Authors:  Jian Xu; Steven H DeVries; Yongling Zhu
Journal:  Hum Gene Ther       Date:  2020-07-14       Impact factor: 5.695

2.  Filling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy.

Authors:  Suriyasri Subramanian; Anna C Maurer; Carol M Bator; Alexander M Makhov; James F Conway; Kevin B Turner; James H Marden; Luk H Vandenberghe; Susan L Hafenstein
Journal:  Hum Gene Ther       Date:  2019-11-14       Impact factor: 5.695

3.  Production and Characterization of Vectors Based on the Cardiotropic AAV Serotype 9.

Authors:  Erik Kohlbrenner; Thomas Weber
Journal:  Methods Mol Biol       Date:  2017

4.  Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension.

Authors:  Caroline Claude; Nathalie Mougenot; Julia Bechaux; Lahouaria Hadri; Damian Brockschnieder; Michel Clergue; Fabrice Atassi; Anne-Marie Lompré; Jean-Sébastien Hulot
Journal:  Mol Ther Methods Clin Dev       Date:  2015-02-04       Impact factor: 6.698

5.  Production of adeno-associated virus vectors for in vitro and in vivo applications.

Authors:  Toyokazu Kimura; Beatriz Ferran; Yuko Tsukahara; Qifan Shang; Suveer Desai; Alessandra Fedoce; David Richard Pimentel; Ivan Luptak; Takeshi Adachi; Yasuo Ido; Reiko Matsui; Markus Michael Bachschmid
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

6.  Comparison of Different Liquid Chromatography-Based Purification Strategies for Adeno-Associated Virus Vectors.

Authors:  Ruth Rieser; Johanna Koch; Greta Faccioli; Klaus Richter; Tim Menzen; Martin Biel; Gerhard Winter; Stylianos Michalakis
Journal:  Pharmaceutics       Date:  2021-05-18       Impact factor: 6.321

7.  Systematic Comparison and Validation of Quantitative Real-Time PCR Methods for the Quantitation of Adeno-Associated Viral Products.

Authors:  Natalie Jayne Werling; Stifani Satkunanathan; Robin Thorpe; Yuan Zhao
Journal:  Hum Gene Ther Methods       Date:  2015-06-09       Impact factor: 2.396

8.  Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.

Authors:  Antoine H Chaanine; Mathieu Nonnenmacher; Erik Kohlbrenner; Dongzhu Jin; Jason C Kovacic; Fadi G Akar; Roger J Hajjar; Thomas Weber
Journal:  Gene Ther       Date:  2014-02-27       Impact factor: 5.250

9.  Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity.

Authors:  Joanne Marie M Del Rosario; Matthew Smith; Kam Zaki; Paul Risley; Nigel Temperton; Othmar G Engelhardt; Mary Collins; Yasuhiro Takeuchi; Simon E Hufton
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

10.  AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease.

Authors:  Michael P Hughes; Dave A Smith; Lauren Morris; Claire Fletcher; Alexandria Colaco; Mylene Huebecker; Julie Tordo; Nuria Palomar; Giulia Massaro; Els Henckaerts; Simon N Waddington; Frances M Platt; Ahad A Rahim
Journal:  Hum Mol Genet       Date:  2018-09-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.